Percentage of data accepted and average statistics for accepted compounds
| Group 1 | Group 2 | |||
|---|---|---|---|---|
| Carvedilol, Diltiazem, Isradipine, Mibefradil, Nicardipine, Quinidine, Ranolazine, Verapamilb | Amiodarone, Felodipine, Nifedipine, Nitrendipine, Sertraline, Telmisartan, Troglitazone | |||
| B>A | A>B | B>A | A>B | |
| Cell-based | ||||
| % tαβ(2p*3p) > 3 | 73 | 52 | 56 | 40 |
| Average tαβ(2p*3p)a | 6.7 ± 3.1 | 5.6 ± 2.3 | 5.6 ± 2.7 | 5.9 ± 3.3 |
| Vesicle-based | ||||
| % tαβ(2p*3p) > 3 | 88 | 80 | ||
| Average tαβ(2p*3p)a | 10.5 ± 6.5 | 7.5 ± 4.5 | ||
↵a Average ± standard deviation for those compounds with tαβ(2p*3p) > 3.
↵b For the PCA analysis a complete set of IC50 values is needed from each participant. Therefore, the PCA analysis was limited to IC50 values from 8 inhibitors (group1) for a total of 24 data sets, using cell line-based as well as vesicle-based IC50 values. Group 2 comprises the remaining seven compounds